Company intelligence / Profile preview

Novexel

Ownership: Private
Development stage: Phase 2

Overview

Novexel specialized in developing novel antibacterial and antifungal agents to treat resistant infections. Their key programs included ceftazidime/NXL-104 (CAZ104) and ceftaroline/NXL-104 (CEF104), which were in late-stage development at the time of acquisition.

Therapeutic areas: Infectious Diseases
Modalities: Small molecules (antibacterial and antifungal agents)
Industry: Biotech

Drug pipeline

2 assets

ceftazidime + NXL-104

Phase 3

Indications: Hospital-acquired pneumonia, Intra-abdominal infections, Urinary tract infections

1 more asset in the full pipeline.

Request access →

Partnerships

Forest Laboratories (for co-development and commercialization of antibiotic programs)

Beyond the preview

Go deeper on Novexel.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Novexel.

Explore the full profile